In addition, the SAVE study is evaluating the stop-and-go strategy in advanced NSCLC enrolling patients who responded to anti-PD-1 agents for over a year, comparing OS in those who stopped therapy in comparison to those who continue (Japan Registry of ClinicalTrials identifier: jRCT1031190032). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.